Private Equity in Dermatology: Navigating RCM During Platform Consolidation

The PE Dermatology Landscape in 2026

Private equity investment in dermatology has reshaped the competitive landscape of the specialty more dramatically than any other force in the past decade. Today, PE-backed platforms and Management Services Organizations (MSOs) control an estimated 35–40% of U.S. dermatology practices by physician count — a figure that was less than 5% in 2015.

This consolidation wave has created enormous value creation opportunities, but also exposed a recurring set of operational vulnerabilities — the most significant of which is revenue cycle performance degradation during platform growth and integration. The pattern is consistent enough to be predictable: a well-performing independent practice is acquired, integrated into a platform, and experiences a 10–20% decline in billing performance during the integration period.

Why Consolidation Disrupts Revenue Cycle Performance

Revenue cycle disruption during PE-backed dermatology consolidation follows a predictable pattern driven by four primary factors. Understanding these factors is the first step toward mitigating their impact.

EHR Migration

EHR migration is the single largest source of billing disruption in acquisition integration. When a practice transitions from its incumbent EHR to the platform's standardized system, the following disruptions occur simultaneously: charge capture workflows change, billing staff must learn new submission processes, clinical documentation templates must be rebuilt, and the historical data in the old system is not always available in the new one.

Practices in our portfolio that have migrated EHRs without a dedicated billing bridge strategy — maintaining the old system for claims that were in process and running both systems in parallel for 90–120 days — experience average revenue disruption of $180,000 per location. Practices that implement a bilingual billing bridge strategy reduce this disruption by 70%.

Billing Staff Transition

When a practice is acquired, the institutional knowledge held by the incumbent billing team — knowledge of payer-specific requirements, modifier rules, pre-authorization workflows — is frequently disrupted by staff turnover, role changes, or transfer of billing responsibilities to a centralized MSO billing team. This knowledge transfer gap is a primary driver of the initial clean claim rate decline.

Contract and Credentialing Continuity

Payer contracts are non-transferable without payer consent. When a practice is acquired, its payer contracts must be re-credentialed under the acquiring entity — a process that typically takes 90–180 days per payer. During this period, claims may be processed under the acquiring entity's existing contract (which may have different rates), under the old practice's contract (if the payer agrees to extend), or held in suspense (not paid at all).

Credentialing gaps — where a newly acquired practice or physician is not yet credentialed with a payer but is seeing patients — create claims that cannot be submitted and may be lost entirely if the credentialing issue is not identified and resolved quickly.

The MSO Standardization Opportunity

Despite the disruption risks, platform consolidation also creates significant RCM improvement opportunities that independent practices cannot access. When executed well, MSO standardization of billing protocols, denial management workflows, and KPI reporting is one of the highest-ROI activities in PE-backed dermatology platform operations.

The practices in our portfolio that have achieved the highest post-integration EBITDA improvements share several characteristics: they maintained specialty-specific billing expertise during and after integration, they implemented a 90-day billing bridge protocol for EHR migrations, they standardized denial management workflows before rolling them out across the portfolio, and they built real-time KPI dashboards that allowed portfolio-level visibility into revenue cycle performance.

Building the RCM Infrastructure for Exit

PE sponsors are increasingly sophisticated about revenue cycle due diligence — both at acquisition and at exit. At exit, a platform with clean KPI documentation, low denial rates, short AR cycles, and a track record of improving billing performance post-acquisition commands a meaningfully higher EBITDA multiple than one that cannot demonstrate these metrics.

The investment in building real-time RCM visibility — clean claim rates by location, denial rates by payer and code, AR aging by bucket, collections as a percentage of net revenue — pays off not only in day-to-day operations but in exit valuation. Buyers discount for revenue cycle uncertainty, and they premium-price for revenue cycle visibility and performance.